Fenofibric acid is a lipid regulating agent available as delayed release capsules for oral administration.
Fenofibric acid activates the peroxisome proliferator activated receptor a (PPARa).
PPARs affect the expression of target genes involved in cell proliferation, cell differentiation and in immune and inflammation responses.
fenofibric Acid is specifically indicated for
1) Co-administration Therapy with Statins for the Treatment of Mixed Dyslipidemia
To reduce TG and increase HDLC in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal.
2) Treatment of Severe Hypertriglyceridemia
3) Treatment of Primary Hyperlipidemia or Mixed Dyslipidemia
To reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C.
The recommended intial dose of the drug for co-administration therapy with statins for the treatment of mixed dyslipidemia is 135 mg daily. Co-administration with the maximum dose of a statin should be avoided.
The recommended initial dose of the drug for severe hypertriglyceridemia is 45 to 135 mg once daily.
The recommended initial dose of the drug for primary hyperlipidemia or mixed dyslipidemia is 135 mg once daily.
Mechanism of Action
fenofibric acid is a lipid regulating agent available as delayed release capsules for oral administration. Fenofibric acid activates the peroxisome proliferator activated receptor a (PPARa). Through this mechanism, fenofibric acid increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of Apo CIII (an inhibitor of lipoprotein lipase activity). The resulting decrease in triglycerides produces an alteration in the size and composition of LDL from small, dense particles to large buoyant particles, which have a greater affinity for cholesterol receptors and are catabolized rapidly. PPARa activation also induces an increase in the synthesis of HDL-C and Apo AI and AII.
Side Effects
* Muscle Pain
* Tenderness
* Weakness
* Tiredness
* Fever
* Abdominal Pain
* Nausea
* Vomiting
A study has shown a steady decline in eGFR without worsening of proteinuria in diabetic CKD pts when using fenofibrate.So it might not be suitable in CKD.Interestingly rosuvastatin was also found to be detrimental in CKD pts (planet 1& 2). Probably gemfibrozil and atorvastatin may be used instead of them.
ReplyDeleteStomach chemicals are crucial in connection with this.
ReplyDeleteThey help to tame the acid in the stomach due to their alkaline nature.
To make you understand it better, lets give an example of the food consumed.
Thanks for your input
Delete